Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial
利利特雷韦单药治疗轻度或中度 COVID-19（不联合利托那韦）：一项多中心、随机、双盲、安慰剂对照的 3 期试验
期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2023.102359
Zhan, Yangqing; Lin, Zhengshi; Liang, Jingyi; Sun, Ruilin; Li, Yueping; Lin, Bingliang; Ge, Fangqi; Lin, Ling; Lu, Hongzhou; Su, Liang; Xiang, Tianxin; Pan, Hongqiu; Huang, Chaolin; Deng, Ying; Wang, Furong; Xu, Ruhong; Chen, Dexiong; Zhang, Ping; Tong, Jianlin; Wang, Xifu; Meng, Qingwei; Zheng, Zhigang; Ou, Shuqiang; Guo, Xiaoyun; Yao, Herui; Yu, Tao; Li, Weiyang; Zhang, Yu; Jiang, Mei; Fang, Zhonghao; Song, Yudi; Chen, Ruifeng; Luo, Jincan; Kang, Changyuan; Liang, Shiwei; Li, Haijun; Zheng, Jingping; Zhong, Nanshan; Yang, Zifeng
